Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients

Masatoshi Ishigami, Takashi Honda, Yoji Ishizu, Yasuharu Onishi, Hideya Kamei, Kazuhiko Hayashi, Yasuhiro Ogura, Yoshiki Hirooka, Hidemi Goto – 25 June 2014 – The combination of nucleos(t)ide analogues (NAs) and hepatitis B immune globulin has been established as safe and effective prophylaxis against hepatitis B virus (HBV) reactivation after liver transplantation (LT). However, the essential weak point of this regimen is its high cost.

Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis

Mélanie Vallin, Olivier Guillaud, Olivier Boillot, Valérie Hervieu, Jean‐Yves Scoazec, Jérôme Dumortier – 25 June 2014 – Nonalcoholic fatty liver disease (NAFLD) is a potential long‐term complication after liver transplantation (LT) and can occur as recurrent disease in patients undergoing transplantation for NAFLD or as de novo NAFLD in others. The aim of this study was to compare these 2 different entities.

Subscribe to